Kenichi Goto
後藤功一
MD, PhD
Chief, Division of Thoracic Oncology胸部肿瘤科部长
👥Biography 个人简介
Dr. Kenichi Goto is Japan's foremost expert on rare oncogenic drivers in NSCLC, with landmark contributions to RET and MET-targeted therapy. His pivotal LIBRETTO-001 and GEOMETRY mono-1 trial work helped establish selective RET and MET inhibitors as standard therapies globally.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
RET-targeted Therapy
Led the Japanese cohort of LIBRETTO-001, demonstrating exceptional response rates of selpercatinib in RET fusion-positive NSCLC and driving global regulatory approval.
MET Exon 14 Skipping
Conducted key studies characterizing MET exon 14 skipping alterations in Japanese NSCLC and establishing capmatinib efficacy, shaping Asian guidelines for MET-targeted therapy.
Rare Driver Research
Established Japan's systematic approach to molecular profiling of rare driver mutations, creating the evidence base for precision medicine in low-prevalence oncogene subsets.
Representative Works 代表性著作
Selpercatinib in Japanese patients with RET fusion-positive non-small-cell lung cancer (LIBRETTO-001)
Cancer Science (2022)
Confirmed 64% ORR of selpercatinib in Japanese RET fusion-positive NSCLC, supporting PMDA approval and establishing RET inhibition as standard care in Japan.
Capmatinib in MET exon 14-mutated non-small-cell lung cancer (GEOMETRY mono-1)
New England Journal of Medicine (2020)
Demonstrated 68% ORR in treatment-naive MET exon 14-skipping NSCLC, establishing capmatinib as the first approved MET-targeted therapy.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
关注 後藤功一 的研究动态
Follow Kenichi Goto's research updates
留下邮箱，当我们发布与 Kenichi Goto（National Cancer Center Hospital East, Japan）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment